Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 3/20 | 0.33 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
| ▸ | ITK | Q08881 | 4/20 | 0.31 |
| ▸ | ABL1 | P00519 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24671283 | 1.00 | RET (0.33) | RETKDRITKABL1 | |
| SCHEMBL29990667 | 1.00 | RET (0.33) | RETKDRITKABL1 | |
| SCHEMBL30863352 | 0.96 | RET (0.32) | RETKDRITK | |
| SCHEMBL24669945 | 0.87 | RET (0.38) | RETKDRITKABL1 | |
| SCHEMBL30066213 | 0.87 | RET (0.38) | RETKDRITKABL1 | |
| SCHEMBL30801213 | 0.84 | ITK (0.37) | RETKDRITK | |
| SCHEMBL18812844 | 0.84 | ITK (0.35) | RETKDRITKABL1 | |
| SCHEMBL30721389 | 0.84 | ITK (0.35) | RETKDRITKABL1 | |
| SCHEMBL24670748 | 0.82 | ITK (0.31) | ITK | |
| SCHEMBL30066236 | 0.82 | ITK (0.31) | ITK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240279202-A1 | COMPOUNDS FOR INHIBITING OR DEGRADING ITK, COMPOSITIONS, COMPRISING THE SAME METHODS OF THEIR MAKING AND METHODS OF THEIR USE | NURIX THERAPEUTICS, INC. | 2024-08-22 | — | — | US | disclosed |
| US-20230158151-A1 | COMPOUNDS FOR INHIBITING OR DEGRADING TARGET PROTEINS, COMPOSITIONS, COMPRISING THE SAME, METHODS OF THEIR MAKING, AND METHODS OF THEIR USE | NURIX THERAPEUTICS, INC. | 2023-05-25 | — | — | US | disclosed |
| US-20230158151-A1 | COMPOUNDS FOR INHIBITING OR DEGRADING TARGET PROTEINS, COMPOSITIONS, COMPRISING THE SAME, METHODS OF THEIR MAKING, AND METHODS OF THEIR USE | NURIX THERAPEUTICS, INC. | 2023-05-25 | — | — | US | disclosed |
| US-20230158151-A1 | COMPOUNDS FOR INHIBITING OR DEGRADING TARGET PROTEINS, COMPOSITIONS, COMPRISING THE SAME, METHODS OF THEIR MAKING, AND METHODS OF THEIR USE | NURIX THERAPEUTICS, INC. | 2023-05-25 | — | — | US | disclosed |
| WO-2022235715-A1 | COMPOUNDS FOR INHIBITING OR DEGRADING ITK, COMPOSITIONS, COMPRISING THE SAME METHODS OF THEIR MAKING AND METHODS OF THEIR USE | NURIX THERAPEUTICS, INC. (US) | 2022-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240279202-A1 | COMPOUNDS FOR INHIBITING OR DEGRADING ITK, COMPOSITIONS, COMPRISING THE SAME METHODS OF THEIR MAKING AND METHODS OF THEIR USE | ITK, NFATC1, TNIK | RET 1724/4885KDR 2126/4885ITK 1/4885 |
| US-20230158151-A1 | COMPOUNDS FOR INHIBITING OR DEGRADING TARGET PROTEINS, COMPOSITIONS, COMPRISING THE SAME, METHODS OF THEIR MAKING, AND METHODS OF THEIR USE | MDM2, XIAP, ADRM1 | RET 3001/4885KDR 3610/4885ITK 4478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.